Nutriterra® Total Omega-3 Receives Health Canada Approval as Plant-Based Dietary Supplement
December 11 2024 - 12:47PM
Nutriterra® Total Omega-3 has received Health Canada approval as an
ingredient in dietary supplements. Health Canada’s Natural and
Non-prescription Health Products Directorate (NNHPD)
issued a product license, Natural Product Number (NPN) 80136254,
which authorizes it to be marketed and sold as a novel,
canola-based total omega-3 oil with the following health claims:
- Supports heart health and cardiovascular function
- Supports normal brain function
- Source of docosahexaenoic acid (DHA) for maintaining good
health
- Source of alpha-linolenic acid (ALA) for maintaining good
health
- Source of an essential fatty acid for the maintenance of good
health
- Source of omega-3 fatty acids for the maintenance of good
health
Nufarm Nutritional general manager, Benita Boettner, said
today’s announcement from NNHPD confirms the nutritional importance
of Nutriterra Total Omega-3 Canola oil. “Health Canada’s approval
recognizes Nutriterra’s ability to support heart and brain health
and provides a new option to meet the growing demand for
plant-based total omega-3 with DHA, EPA, and ALA.”
Human clinical trials confirmed that Nutriterra’s long-chain
fatty acids are readily incorporated into blood lipids. Results
were reviewed and authorized by NNHPD and published in Frontiers in
Nutrition in 2022. A 2000 mg/day serving of Nutriterra
significantly improved indicators of omega-3 status, including the
OmegaScore™ and the Omega-3 Index, both of which are
supportive of cardiovascular and brain health.
While the health benefits of omega-3 fatty acids are well known,
few people consume enough of these essential nutrients. Ms.
Boettner attributes this to the sensory experiences and ocean
health concerns associated with fish oil. She says, “With Health
Canada’s approval for Nutriterra as a safe and effective dietary
ingredient, we are well placed to attract new consumers and raise
consumption of omega-3 closer to the recommended daily intake.”
This approval follows the Canadian Food Inspection Agency’s 2020
approval of Nutriterra for food and feed applications, allowing for
greater formulation flexibility for our customers.
Omega-3 Canola helps fill the gap between how much long-chain
omega-3 is needed to support human health and how little the ocean
can sustainably provide. Just one hectare of Nuseed Omega-3 canola
produces as much DHA as 10,000 one kg wild caught fish. Nutriterra
has a unique fatty acid profile with DHA, EPA, and ALA to support
human nutrition.
This Health Canada approval follows the US Food and Drug
Administration (FDA) granting Nutriterra New Dietary Ingredient
status in 2021. Having previously obtained food and feed approvals
in Australia and New Zealand, the US, and Canada, the company is
progressing with additional regulatory applications in other key
markets around the world.
About Nutriterra
Nutriterra® is designed for human nutrition from proprietary
Omega-3 Canola, the world’s first plant-based source of long-chain
omega-3 fatty acids. Nutriterra provides a sustainable land-based
oil supply, helping reduce pressure on wild fish stocks and closing
the gap between how much omega-3 is needed to support human health
and how little the ocean can provide. Learn more at
nutriterraomega3.com.
Nutriterra is a nutritional product of Nufarm Limited.
(ASX:NUF). Nufarm’s seed technologies platform is enabling the
transformation of key crops into renewable and traceable sources of
plant-based nutrition and lower carbon energy. Our proprietary
solutions contribute to solving global challenges like food
security, human nutrition, and climate change.
Further information:
Katrina
BenedictoMarketing & Communications Director,
Omega-3katrina.benedicto@nuseed.com + 1 530 490 1038
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/4f019d2a-41de-4e17-9ec3-e87673b23912
Nufarm (ASX:NUF)
Historical Stock Chart
From Dec 2024 to Jan 2025
Nufarm (ASX:NUF)
Historical Stock Chart
From Jan 2024 to Jan 2025